VAERS Explorer
Back to explore

Report #2894581

Received May 12, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
29 yrs
State
TX
Recovered
Unknown
Vaccinated
Apr 27, 2026
Onset
Apr 27, 2026
Days to onset
0
Hospital days

Vaccines (2)

TypeNameManufacturerDoseLotRoute / Site
TYPTYPHOID VI POLYSACCHARIDE (TYPHIM VI)SANOFI PASTEUR1Y2A41P1IM / LA
TYPTYPHOID VI POLYSACCHARIDE (TYPHIM VI)SANOFI PASTEURUNKY2A41P1IM / RA

Symptoms (2)

Extra dose administeredNo adverse event

Symptom narrative

inadvertently gave 2 shots of TYPHIM VI PFS at the same visit of their patient this morning, with no reported adverse event; Initial information received on 27-Apr-2026 regarding an unsolicited valid non-serious case received from a nurse. This case involves a 29-year-old male patient who was inadvertently given 2 shots of typhoid VI polysaccharide vaccine (TYPHIM VI) at the same visit this morning, with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s), and family history were not provided. Concomitant medications included Vimkunya (chikungunya virus vaccine VLP r C,E1,E2 (HEK293)) and Ixiaro (Japanese encephalitis vaccine inact). On 27-Apr-2026, the patient received a 0.5 mL dose of typhoid VI polysaccharide vaccine [TYPHIM VI] solution for injection (batch number: Y2A41P1, expiry date: 31-Oct-2027) (strength: standard) via intramuscular route in right deltoid and on the same day, the patient again received 0.5 ml of same vaccine in left arm and thus was inadvertently given 2 shots at the same visit this morning, with no reported adverse event for immunization (extra dose administered, latency: same day). Action taken: not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medication error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Medical history

Comments: NONE

Other medications

Vimkunya; Ixiaro